|Articles|March 1, 2006

Pharmacy Times

  • Volume 0
  • 0

Azithromycin for Injection

AmericanPharmaceuticalPartners(Schaumburg,Ill) recently receivedFDA approvalfor its abbreviatednew drug applicationfor Azithromycin forInjection. The product is the genericequivalent of Pfizer Inc's Zithromax.Azithromycin for Injection is indicated forthe treatment of community-acquiredpneumonia and pelvic inflammatory disease,when caused by susceptiblemicroorganisms. The product will beavailable in 500-mg vials. Azithromycinfor Injection is preservative-free, andeach vial will include a bar code andlatex-free vial stopper. For more information,visit www.appdrugs.com.

Articles in this issue

almost 20 years ago

Suing a Lawyer for Malpractice?

almost 20 years ago

Pharmacists—Cops or Not? (Part 1)

almost 20 years ago

Can You Read These Rxs?

almost 20 years ago

Compounding Hotline

almost 20 years ago

Obesity May Lead to Kidney Failure

almost 20 years ago

Midlife Obesity May Cause Heart Disease

almost 20 years ago

The Evolution of Imprint Identification

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME